Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Phase 3

Completed

Conditions: Community Acquired Bacterial Pneumonia

Interventions: Drug: Moxifloxacin
Drug: Delafloxacin
Drug: Linezolid

First Posted Date: 2016-02-10

Last Posted Date: 2020-02-27

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 860

Registration Number: NCT02679573

Locations: 🇺🇦
Melinta 306 Study Site, Zhytomyr, Ukraine

Thorough QT Study of Intravenous Amisulpride

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: APD421 5 mg
Drug: APD421 40 mg
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2016-01-22

Last Posted Date: 2018-11-29

Lead Sponsor: Acacia Pharma Ltd

Target Recruit Count: 40

Registration Number: NCT02661594

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-63623872 2400 milligram (mg)
Drug: JNJ-63623872 3000 mg
Drug: JNJ-63623872
Drug: Placebo (Matching with JNJ-63623872 2400 mg)
Drug: Placebo (Matching with JNJ-63623872 3000 mg)
Drug: Moxifloxacin
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)

First Posted Date: 2016-01-20

Last Posted Date: 2016-06-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 66

Registration Number: NCT02658825

Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Drug - Placebo
Drug: Moxifloxacin
Drug: Sertraline

First Posted Date: 2016-01-11

Last Posted Date: 2021-01-27

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 54

Registration Number: NCT02651623

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

Phase 1

Completed

Conditions: Healthy Adult Male and Female Volunteers

Interventions: Drug: Placebo
Drug: Exenatide
Drug: Moxifloxacin
Drug: Palonosetron

First Posted Date: 2016-01-08

Last Posted Date: 2017-01-27

Lead Sponsor: Intarcia Therapeutics

Target Recruit Count: 82

Registration Number: NCT02650479

Locations: 🇳🇱
PRA-Groningen, Groningen, Netherlands

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Drug - placebo
Drug: Moxifloxacin
Drug: Venlafaxine

First Posted Date: 2015-12-22

Last Posted Date: 2021-01-27

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 54

Registration Number: NCT02637193

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis

Phase 2

Completed

Conditions: Endophthalmitis

Interventions: Drug: Moxifloxacin

First Posted Date: 2015-11-03

Last Posted Date: 2019-04-24

Lead Sponsor: Universidade Federal de Pernambuco

Target Recruit Count: 1000

Registration Number: NCT02595359

Locations: 🇧🇷
UFPE Ophthalmology, Recife, PE, Brazil

Intracameral Antibiotic Safety Study

Phase 3

Suspended

Conditions: Vancomycin
Moxifloxacin
Intracameral Antibiotics
Cataract Surgery
Phacoemulsification
Endophthalmitis

Interventions: Drug: Placebo
Drug: Vancomycin
Drug: Moxifloxacin

First Posted Date: 2015-10-29

Last Posted Date: 2022-04-27

Lead Sponsor: Panhandle Eye Group, LLP

Target Recruit Count: 500

Registration Number: NCT02590523

Locations: 🇺🇸
Rush Eye, Amarillo, Texas, United States

Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

Phase 2

Completed

Conditions: Tuberculosis, Multidrug-Resistant
Extensively Drug-Resistant Tuberculosis
Tuberculosis, Pulmonary

Interventions: Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
Drug: Bedaquiline
Drug: Pretomanid
Drug: Moxifloxacin
Drug: Linezolid
Drug: Clofazimine

First Posted Date: 2015-10-28

Last Posted Date: 2024-05-01

Lead Sponsor: Medecins Sans Frontieres, Netherlands

Target Recruit Count: 552

Registration Number: NCT02589782

Locations: 🇿🇦
King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇺🇿
Republican TB Hospital No. 2, Nukus, Karakalpakstan, Uzbekistan
🇧🇾
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus

and more 4 locations

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Phase 3

Conditions: Tuberculosis

Interventions: Drug: Rifampin
Drug: Rifapentine
Drug: Isoniazid
Drug: Moxifloxacin
Drug: Pyrazinamide
Drug: Ethambutol
Dietary Supplement: Pyridoxine

First Posted Date: 2015-09-30

Last Posted Date: 2017-03-01

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 60

Registration Number: NCT02563327

Locations: 🇺🇬
Mulago Hospital, Kampala, Uganda

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy